Over-expression of epidermal growth factor receptor and c-erbB2/neu but not ofint-2 genes in benign prostatic hyperplasia by means of semi-quantitative PCR

Caceres, Carme; Morote, J.; Torres, Inés de; Rodríguez-Vallejo, José M.; González, Jorge Cuevas; Reventós, Jaume

doi:10.1002/(sici)1097-0215(19980518)76:4<464::aid-ijc3>3.0.co;2-p

Cited by 19 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding was not unexpected, and in fact, it has been previously described [6,39,40]. It is known that the biologic function of growth factors and receptors such as HER2 can be different in tumor cells, compared with their normal counterparts.…”

Section: Discussionsupporting

confidence: 75%

HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer

et al. 2006

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 75%

HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer

et al. 2006

View full text Add to dashboard Cite

“…Slamon et al 17 were the first to show that Her-2/neu gene amplification and protein overexpression is associated with an increase risk of relapse and death in patients with breast cancer. Since then several investigators [21][22][23][24][25][26][27][30][31][32][33][34][35][36][37][38][39][40][41] have explored the role of Her-2/neu oncogene in PCa progression and metastasis.…”

Section: Discussionmentioning

confidence: 99%

“…20 However, prognostic value of Her-2/neu expression in PCa is controversial, and most studies have limited number of cases with shortterm follow-up. [21][22][23][24][25][26][27] The current study utilizing PCa tissue sections has assessed the prognostic value of Her-2/neu expression and DNA content for prediction of progression, metastasis and PCa-specific death after radical prostatectomy in 252 men with mean follow-up duration of 15.3 years.…”

mentioning

confidence: 99%

Prognostic value of Her‐2/neu and DNA index for progression, metastasis and prostate cancer‐specific death in men with long‐term follow‐up after radical prostatectomy

Isharwal

Miller

Epstein

et al. 2008

Intl Journal of Cancer

View full text Add to dashboard Cite

Abnormal DNA content in tumor cells represents large scale chromosomal alterations and reflects later changes of genetic instability. Her-2/neu oncogene is amplified in 20-30% of breast and ovarian cancer patients and is associated with poor prognosis. Therefore, we evaluated prognostic value of Her-2/neu expression and DNA content measurements in 252 clinically localized PCa patients with long-term follow-up after radical prostatectomy for progression, metastasis and PCa-specific death. Her-2/neu expression was determined by immunohistochemistry and DNA content measurements employed Feulgen-stained cancer nuclei captured using static image cytometry system. Cox proportional hazard regression and Kaplan-Meir plots were used to identify significant prognostic factors for progression, metastasis and PCa-specific death. The proportions of Her-2/neu positive and high %DNA index tumors significantly increased from nonprogressor to progressors without metastasis to progressors with metastasis (p < 0.0001; <0.0001). Further, the proportions of Her-2/neu positive and high %DNA index tumors significantly increased from patients who died from another cause without progression to those who died from another cause with progression to those died with PCa-specific death (p 5 0.027; <0.0001). Her-2/neu expression and %DNA index were significant prognosticators for progression (p 0.001), metastasis (p 0.01) PCa-specific death (p 0.04) in univariate analyses. Multivariately, Her-2/neu expression and %DNA index were also significant for progression (p 5 0.001), metastasis (p 5 0.001) and PCa-specific death (p 5 0.02). When all other clinicopathologic information is available, the increment in concordance index by addition of either Her-2/neu or DNA index was 2% and of both biomarkers was 3% for progression, metastasis and PCa-specific death free survival models. Therefore, patients with Her-2/neu positive and high %DNA index are at a higher risk for disease progression, metastasis and PCa-specific death. Further, Her-2/neu expression and %DNA index may be used with clinicopathologic parameters for prediction of longterm prognosis in PCa. ' 2008 Wiley-Liss, Inc.Key words: prostate cancer; Her-2/neu; DNA index; progression; metastasis; PCa-specific death; prognosis Prostate cancer (PCa) is the second leading cause of cancer death among men in the United States, with an anticipated 186,320 newly diagnosed cases and 28,660 deaths in 2008.1 The majority of men with clinically localized PCa are treated with radical prostatectomy which provides excellent cancer control and minimal surgical complications. In a series of 1,997 patients treated with radical prostatectomy at the Johns Hopkins Hospital, Pound et al.2 identified 304 men who developed PSA recurrence (15%) and were monitored without hormone therapy before demonstration of metastasis. Of the 304 men, 34% developed distant metastases over a median period of 8 years from the time of the first postoperative PSA elevation. An algorithm was developed by combining Gleason score, PSA ...

show abstract

“…The realtime PCR methods we have used are based on a kinetic analysis of the amplification curve. [35][36][37][38][39] At present, real-time PCR system is seemed to be the most sensitive and rapid system for the quantitation of DNA and RNA. 40 Real-time PCR systems were improved by probe-based, rather than intercalator-based PCR product detection.…”

Section: Discussionmentioning

confidence: 99%

O⁶‐methylguanine‐DNA methyltranspherase gene expression in gliomas by means of real‐time quantitative RT‐PCR and clinical response to nitrosoureas

Tanaka

Kobayashi

Utsuki

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

Key words: MGMT; real-time RT-PCR; ACNU; gliomaNitrosoureas are alkylating agents that cause cell death by binding to DNA. Among nitrosoureas, 1-(4-amino-2-methyl-5-pyrimidynyl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) is widely used in Japan to treat gliomas because of its ability to permeate the blood-brain-barrier and excellent clinical effects in combination with radiation and interferon (IFN)-␤. [1][2][3] Drug-resistance genes are some of the most important elements of tumors themselves in determining drug-resistance, 4 and O 6 -methylguanine-DNA methyltransferase (MGMT) is a drug-resistance gene for nitrosoureas. 5,6 The cross-linking of doublestranded DNA by alkylating agents is inhibited by the cellular DNA-repair protein MGMT. MGMT rapidly reverses alkylation at the O 6 position of guanine, thereby averting lethal cross-linking. 7 This is the mechanism by which MGMT induces resistance to alkylating agents such as ACNU.Protocol studies for malignant gliomas have not provided encouraging therapeutic results because of the heterogeneity and various drug-sensitivities of the tumors. 8,9 Individualization of glioma therapy is recommended. We carried out a new adjuvant therapy that was individualized based on the results of the reverse transcription-polymerase chain reaction (RT-PCR) for MGMT to treat malignant gliomas. 2 Our preliminary individual adjuvant therapies (IAT) based on RT-PCR results regarding MGMT expression seemed to be more effective than conventional therapies for malignant gliomas.The level of MGMT varies widely according to the type of tumor, and even varies among tumors of the same histological classification. 5,10 Approximately 30 -50% of gliomas lack MGMT. 11 The fact that more than 50% of gliomas express MGMT limits the indications for ACNU. In our preliminary IAT, platinum (Pt)-compounds were used instead of ACNU even though Ptcompounds had not been accepted as being effective in gliomas. 12,13 To ensure IAT for gliomas, quantitative evaluation is needed for a higher initial response and prolongation of survival.We carried out the present study to determine more appropriate indications for the use of ACNU in gliomas. Real-time quantitative RT-PCR was used to re-evaluate the treated gliomas. MATERIAL AND METHODS Real-time quantitative RT-PCRIn 100 frozen sample of neuroepithelial tumors (19 low-grade neuroepithelial tumors, 28 Grade III gliomas, 41 glioblastomas, and 12 medulloblastomas), MGMT was quantitated by real-time quantitative RT-PCR using SYBR Green dye. RT-PCR was basically carried out as described previously. 14 -16 Briefly, total RNA was extracted from frozen tissue specimens weighing about 1 g, which had been homogenized using a glass Teflon homogenizer, via the guanidinium thiocyanate-phenol-chloroform single-step extraction method with Isogen (Nippon Gene, Toyama, Japan). 17 After ethanol precipitation, about 100 g of total RNA was extracted. Forty microliters of complementary deoxyribonucleic acid (cDNA) solution was synthesized from 2 g of total RNA wi...

show abstract

Over-expression of epidermal growth factor receptor and c-erbB2/neu but not ofint-2 genes in benign prostatic hyperplasia by means of semi-quantitative PCR

Cited by 19 publications

References 28 publications

HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer

HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer

Prognostic value of Her‐2/neu and DNA index for progression, metastasis and prostate cancer‐specific death in men with long‐term follow‐up after radical prostatectomy

O⁶‐methylguanine‐DNA methyltranspherase gene expression in gliomas by means of real‐time quantitative RT‐PCR and clinical response to nitrosoureas

Contact Info

Product

Resources

About

Over-expression of epidermal growth factor receptor and c-erbB2/neu but not ofint-2 genes in benign prostatic hyperplasia by means of semi-quantitative PCR

Cited by 19 publications

References 28 publications

HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer

HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer

Prognostic value of Her‐2/neu and DNA index for progression, metastasis and prostate cancer‐specific death in men with long‐term follow‐up after radical prostatectomy

O6‐methylguanine‐DNA methyltranspherase gene expression in gliomas by means of real‐time quantitative RT‐PCR and clinical response to nitrosoureas

Contact Info

Product

Resources

About

O⁶‐methylguanine‐DNA methyltranspherase gene expression in gliomas by means of real‐time quantitative RT‐PCR and clinical response to nitrosoureas